Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 20, 2026, reports a significant regulatory milestone in China. The National Medical Products Administration (NMPA) has approved Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
Key Financial and Operational Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on clinical trial data and regulatory status.
- Regulatory Status: Approved in China (NMPA) for 2L+ relapsed/refractory multiple myeloma.
- Global Approvals: Blenrep has received more than 15 regulatory approvals globally, including the US, EU, UK, Japan, Canada, Switzerland, Brazil, and Australia.
- Market Context: Multiple myeloma incidence in China has doubled to approximately 30,000 new cases annually.
Material Changes and Clinical Data
The approval is supported by data from the pivotal DREAMM-7 Phase III trial, which demonstrated statistically significant improvements over the daratumumab-based triplet (DVd) comparator:
- Overall Survival (OS): A 42% reduction in the risk of death (Hazard Ratio 0.58; p=0.00023). The three-year OS rate was 74% for BVd versus 60% for DVd.
- Progression-Free Survival (PFS): Median PFS nearly tripled to 36.6 months for BVd compared to 13.4 months for DVd (Hazard Ratio 0.41).
- Safety Profile: Eye-related side effects were manageable with dose modifications, resulting in discontinuation rates of ≤9%. Common non-ocular adverse events included thrombocytopenia (87%) and diarrhea (32%).
Outlook, Management Commentary, and Risks
Management Commentary: Hesham Abdullah, Senior Vice President of Global Head Oncology, R&D, emphasized that Blenrep introduces a differentiated mechanism of action as the only anti-BCMA antibody-drug conjugate (ADC) approved in China for this indication. He highlighted the benefit of it being a fully outpatient therapy, minimizing patient and healthcare burden.
Outlook: GSK aims to expand its oncology portfolio into lung and gastrointestinal cancers while accelerating priority programs such as antibody-drug conjugates targeting B7-H3 and B7-H4.
Risks: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2025.
Key Facts for Investor Verification
- Verify the commercial launch timeline and pricing strategy for Blenrep in the Chinese market following NMPA approval.
- Confirm the specific revenue contribution of Blenrep in the upcoming quarterly earnings reports, given the recent approvals in the US, EU, and China.
- Monitor the long-term safety data regarding eye-related adverse events as real-world usage expands.
- Review the "Risk Factors" section of the 2025 Form 20-F for details on regulatory and competitive risks in the oncology sector.